Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
Bascom Palmer Eye Institute, Miami, Florida Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida